P‐CB‐21 | RBC Alloimmunization Responder Type and COVID‐19 Vaccine IgG Response in Patients with Sickle Cell Disease.

MLA

Nakahara, H., et al. “P‐CB‐21 | RBC Alloimmunization Responder Type and COVID‐19 Vaccine IgG Response in Patients with Sickle Cell Disease.” Transfusion, vol. 63, Oct. 2023, p. 159A–160A. EBSCOhost, https://doi.org/10.1111/trf.204_17554.

APA

Nakahara, H., Cheedarla, N., Verkerke, H., Cheedarla, S., Wu, S., Hendrickson, J., Roback, J., Neish, A., Fasano, R., & Stowell, S. (2023). P‐CB‐21 | RBC Alloimmunization Responder Type and COVID‐19 Vaccine IgG Response in Patients with Sickle Cell Disease. Transfusion, 63, 159A–160A. https://doi.org/10.1111/trf.204_17554

Chicago

Nakahara, H., N. Cheedarla, H. Verkerke, S. Cheedarla, S. Wu, J. Hendrickson, J. Roback, A. Neish, R. Fasano, and S. Stowell. 2023. “P‐CB‐21 | RBC Alloimmunization Responder Type and COVID‐19 Vaccine IgG Response in Patients with Sickle Cell Disease.” Transfusion 63 (October): 159A–160A. doi:10.1111/trf.204_17554.